Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/jspui/handle/10553/149414
| Title: | Extra-virgin olive oil and additional cardiovascular outcomes in the PREDIMED Trial: An outcome-wide perspective | Authors: | de Rojas, Javier Pérez Toledo, Estefania Estruch, Ramón Guasch-Ferré, Marta Salas-Salvadó, Jordi Gómez-Gracia, Enrique Ros, Emilio Fitó, Montse Arós, Fernando Fiol, Miquel Lapetra, José Serra Majem, Luis Pintó, Xavier Sorlí, José V. Babio, Nancy Castañer, Olga Alonso-Gómez, Ángel M. Martínez-González, Miguel Ángel Jiménez-Moleón, José Juan |
UNESCO Clasification: | 32 Ciencias médicas 320501 Cardiología 3206 Ciencias de la nutrición |
Keywords: | Peripheral Artery-Disease Mediterranean Diet Heart-Failure Risk Consumption, et al |
Issue Date: | 2025 | Journal: | The American heart journal | Abstract: | Background: Olive oil, increasingly consumed in the U.S., has been inversely associated with cardiovascular disease (CVD) risk. However, previous studies did not assess a broad spectrum of CVD outcomes, incorporated repeated annual dietary assessments, or distinguished between polyphenol-rich EVOO and common olive oil (COO), which lacks these compounds. Methods: We assessed 7102 high-risk participants from the PREDIMED trial (57.5% women; aged 55-80 years), all free of CVD at baseline. Olive oil consumption was assessed annually, and cumulative average intakes of EVOO and COO were calculated. The primary outcome was a composite of myocardial infarction, stroke, peripheral arterial disease, heart failure, atrial fibrillation, or cardiovascular death, whichever occurred first. Individual outcomes were also evaluated. Time-dependent Cox models were adjusted for major confounders, including trial intervention arm. Results: Over a median follow-up of 4.7 years, 621 participants experienced at least one CVD event. Participants in the highest tertile of cumulative EVOO intake (mean: 49.2 g/d) had a 25% lower risk of the composite outcome (HR: 0.75; 95% CI: 0.60-0.94), with significant reductions in several individual CVD outcomes. In the decile analysis, the highest (mean: 60.9 g/d) versus lowest decile had a 48% lower risk (HR: 0.52; 95% CI: 0.35 to 0.79). COO consumption was not significantly associated with CVD risk when mutually adjusted for EVOO (HRper 10 g/d: 0.93; 95% CI: 0.87-1.00). Conclusions: High consumption of EVOO is associated with a substantial reduction in the risk of an outcome-wide composite of CVD events among high-risk individuals. In contrast, COO, which lacks polyphenols, showed weaker associations, highlighting the importance of differentiating olive oil types in CVD prevention strategies. Trial Registration: This trial was registered in the ISRCTN registry (ISRCTN 35739639): https://www.isrctn.com/ISRCTN35739639. | URI: | https://accedacris.ulpgc.es/jspui/handle/10553/149414 | ISSN: | 0002-8703 | DOI: | 10.1016/j.ahj.2025.08.021 | Source: | American Heart Journal[ISSN 0002-8703],v. 291, p. 175-185, (Enero 2026) |
| Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.